ARIAD to Present at the Jefferies 2016 Global Healthcare Conference
Get Alerts ARIA Hot Sheet
Join SI Premium – FREE
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Jefferies 2016 Global Healthcare Conference being held in New York City. Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company’s business on Wednesday, June 8, 2016 at 11:00 a.m. (ET).
The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://www.ariad.com/investor. A replay of the presentation will also be available and archived on the site for three weeks.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is an orphan oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat orphan cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).
View source version on businesswire.com: http://www.businesswire.com/news/home/20160601005189/en/
ARIAD Pharmaceuticals, Inc.
For Investors
Maria Cantor,
617-621-2208
[email protected]
or
For
Media
Liza Heapes, 617-621-2315
[email protected]
Source: ARIAD Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MoneyHero Group Reports Unaudited First Quarter 2026 Results
- Deloitte CFO Signals™ (Q226): As Confidence Recedes, CFOs Own Company Optimism Rises
- BIGG Digital Assets Announces Acceptance of Netcoins CIRO Membership Application
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Jefferies & Co, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share